Drug Trial Radar · NCT07241546
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Mar 30, 2026
Primary completion
Dec 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
Conditions
- Asthma
Interventions
ARO-RAGEDrug
Inhalation of nebulized solution
PlaceboDrug
Calculated volume to match active treatment by inhalation of nebulized solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline Over Time in Maximum Area of ReactanceTime frame: Baseline through Day 58
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Research Site 2
Calgary, Canada · Recruiting
Research Site 3
Edmonton, Canada · Recruiting
Research Site 5
Hamilton, Canada · Recruiting
Research Site 6
Québec, Canada · Recruiting
Research Site 4
Saskatoon, Canada · Recruiting
Research Site 1
Vancouver, British Columbia, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.